Status:
RECRUITING
Ultralow Dose PET Imaging for PSMA Expression
Lead Sponsor:
Akiva Mintz
Conditions:
Healthy Volunteer
Prostate CA
Eligibility:
All Genders
18-120 years
Phase:
PHASE2
Brief Summary
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for prostate cancer detection and monitoring. The main question it aims to answer is: Can the inv...
Detailed Description
This research study aims to evaluate an investigational ultralow dose PET imaging technique for prostate cancer detection and monitoring. "Investigational" means that the procedure or drug being studi...
Eligibility Criteria
Inclusion
- Age ≥18 years.
- Ability to provide informed consent and comply with study procedures.
- For female participants:
- Must not be pregnant or breastfeeding.
- Negative pregnancy test required for women of childbearing potential.
Exclusion
- Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 mSv total).
- More than four prior enrollments in this study.
- Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan
- Medication \& Prior Treatment Exclusions
- • Concurrent PSMA-targeted therapy (e.g., lutetium-177).
- Pregnant or breastfeeding individuals (negative pregnancy test required)
- Inability to provide informed consent
- Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.
Key Trial Info
Start Date :
May 12 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2030
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06904313
Start Date
May 12 2025
End Date
June 30 2030
Last Update
June 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nuclear Imaging Institute
Englewood, New Jersey, United States, 07631